AOD9604 5mg

AOD9604 is a modified peptide fragment of human growth hormone, made up of the hGH 176-191 C-terminal sequence with an added tyrosine. It was developed by Metabolic Pharmaceuticals in Melbourne, Australia, and is studied within metabolic and lipolytic pathway research. PhaseOne supplies AOD 9604 5mg as a lyophilised research powder.

No. AOD9604 corresponds to only a short C-terminal section of the human growth hormone molecule — residues 176 to 191 — rather than the full 191-amino-acid hormone. Because it lacks the remainder of the sequence, it is studied as a distinct fragment and research findings on growth hormone do not automatically transfer to it. It is also listed under the names AOD-9604 and hGH fragment 176-191.

No. AOD9604 is not approved by the FDA as a medicine, and it is not registered on the Australian Register of Therapeutic Goods either. It is supplied strictly as a research compound, and PhaseOne makes no therapeutic claims about it.

Cloudiness after reconstitution is usually incomplete dissolution rather than a fault with the peptide. Lyophilised powder needs the solvent run gently down the side of the vial and then swirled, not shaken — agitation causes foaming and can leave the solution looking milky. Cold solvent also dissolves more slowly. If a solution stays persistently cloudy or shows visible particles after settling, stop and check the batch COA. (!) Read our reconstitution guide.

PhaseOne ships AOD9604 Australia-wide for research use, dispatched locally with tracking, in 5mg vials. Every vial carries a batch-specific Certificate of Analysis verifying ≥99% HPLC purity, so Australian researchers are not relying on overseas listings or unverified stock.

Yes — PhaseOne has AOD 9604 for sale online in 5mg vials, shipped Australia-wide. Listings appear under several spellings, including AOD-9604, AOD9604 and hGH fragment 176-191, which all refer to the same compound. PhaseOne supplies it as a lyophilised research powder with a batch Certificate of Analysis.

PhaseOne prices AOD9604 at A$71.99 for a 5mg vial, reduced from A$89.99, with the batch Certificate of Analysis included at no extra cost. Current pricing is shown on this page.

No. AOD9604 is not registered on the ARTG and is not approved for supply as a medicine in Australia, so Chemist Warehouse and other Australian chemists do not stock it. It is supplied as a research compound through research suppliers instead.

Published AOD9604 research has examined lipolytic signalling and lipid metabolism pathways associated with the C-terminal region of growth hormone, separated from the growth-promoting activity of the full molecule. The compound originated in Australian research at Metabolic Pharmaceuticals in Melbourne during the 1990s and remains a closely followed fragment in metabolic research.

AOD9604 is supplied as a lyophilised powder for improved stability during storage and shipping across Australia. Unreconstituted vials should be kept refrigerated and protected from direct light, and are commonly reconstituted using bacteriostatic water prior to research preparation. (!) Read our reconstitution guide or bacteriostatic water guide.

As interest in research peptides grows across Australia, transparency and third-party testing have become increasingly important to Australian peptide buyers. All PhaseOne research peptides are supported by third-party HPLC testing, verified COA reporting, research-grade manufacturing standards, and Australia-wide access. (!) View our COA library.

HPLC testing refers to High Performance Liquid Chromatography, an analytical method used to verify peptide purity and compound identity - a standard PhaseOne applies to every research peptide sold in Australia.